pragma.vision Technology observatory & strategic foresight

Verification register Bio, Health & Neuro

Readiness verdict

PM577a (in vivo Prime Editor for Wilson Disease)

A dated reading of what is claimed, reported, and independently verified in the current evidence.

As of
2026-08-20
Revision
1
Method
v1.3.0

Current reading

Readiness band and full integer triple

AI-assisted assembly · derived results

Readiness band

Emerging

Primary summary from verified readiness

Confidence
68% · stale
Computed at
2026-08-20T10:53:39.490184+00:00
Claimed
40

Public ambition and stated capability

Reported
35

Observed practitioner reporting

Verified
31

Independently supported evidence

Gap
+9

Claimed leads verified

Evidence strength Strong

Decision

What the current evidence supports

Human editorial judgment · 2026-08-20

Too early to adopt

Why
This is the first in vivo prime-editing CTA clearance — a notable platform milestone — but there is zero human data, a constrained cash runway, and single-mutation scope, so it is a watch-list item, not an adoptable capability.
Next
Wait for the first-in-human safety/biological-activity readout in 2027 (copper efflux via 64Cu PET, ceruloplasmin, urinary copper) before treating in vivo prime editing as clinically de-risked.

Constraints

Blockers

No named blocker is present in the current public projection.

Evidence summary

Derived counts

AI-assisted assembly

Total
11
Tier 1
0
Tier 2
4
Tier 3
7
Supports
1
Contradicts
4
Context
6
Latest observed
2026-07-20

Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.

Publication record

Revisions

Initial public reading

  1. 2026-07-19 Reading moved from emerging to emerging.

Your opinion

Tell us anything.

What works, what doesn't, what's missing — especially about our watches, lenses, and the register itself. Anonymous is fine; leave an email if you'd like a reply.